Hindley Stephen, Ward Stephen A, Storr Richard C, Searle Natalie L, Bray Patrick G, Park B Kevin, Davies Jill, O'Neill Paul M
Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, Liverpool L69 7ZD, UK.
J Med Chem. 2002 Feb 28;45(5):1052-63. doi: 10.1021/jm0109816.
The potent antimalarial activity of chloroquine against chloroquine-sensitive strains can be attributed, in part, to its high accumulation in the acidic environment of the heme-rich parasite food vacuole. A key component of this intraparasitic chloroquine accumulation mechanism is a weak base "ion-trapping" effect whereupon the basic drug is concentrated in the acidic food vacuole in its membrane-impermeable diprotonated form. By the incorporation of amino functionality into target artemisinin analogues, we hoped to prepare a new series of analogues that, by virtue of increased accumulation into the ferrous-rich vacuole, would display enhanced antimalarial potency. The initial part of the project focused on the preparation of piperazine-linked analogues (series 1 (7-16)). Antimalarial evaluation of these derivatives demonstrated potent activity versus both chloroquine-sensitive and chloroquine-resistant parasites. On the basis of these observations, we then set about preparing a series of C-10 carba-linked amino derivatives. Optimization of the key synthetic step using a newly developed coupling protocol provided a key intermediate, allyldeoxoartemisinin (17) in 90% yield. Further elaboration, in three steps, provided nine target C-10 carba analogues (series 2 (21-29)) in good overall yields. Antimalarial assessment demonstrated that these compounds were 4-fold more potent than artemisinin and about twice as active as artemether in vitro versus chloroquine-resistant parasites. On the basis of the products obtained from biomimetic Fe(II) degradation of the C-10 carba analogue (23), we propose that these analogues may have a mode of action subtly different from that of the parent drug artemisinin (series 1 (7-16)) and other C-10 ether derivatives such as artemether. Preliminary in vivo testing by the WHO demonstrated that four of these compounds are active orally at doses of less than 10 mg/kg. Since these analogues are available as water-soluble salts and cannot form dihydroartemisinin by P450-catalyzed oxidation, they represent useful leads that might prove to be superior to the currently used derivatives, artemether and artesunate.
氯喹对氯喹敏感菌株具有强大的抗疟活性,部分原因是其在富含血红素的寄生虫食物泡的酸性环境中高度蓄积。这种寄生虫内氯喹蓄积机制的一个关键组成部分是弱碱“离子捕获”效应,即碱性药物以其膜不可渗透的双质子化形式浓缩在酸性食物泡中。通过将氨基官能团引入目标青蒿素类似物中,我们希望制备一系列新的类似物,凭借其在富含亚铁的液泡中蓄积增加,显示出增强的抗疟效力。该项目的初始部分集中于制备哌嗪连接的类似物(系列1(7 - 16))。对这些衍生物的抗疟评估表明,它们对氯喹敏感和氯喹耐药寄生虫均具有强大活性。基于这些观察结果,我们接着着手制备一系列C - 10碳环连接的氨基衍生物。使用新开发的偶联方案对关键合成步骤进行优化,以90%的产率提供了关键中间体烯丙基脱氧青蒿素(17)。通过三步进一步精细合成,以良好的总产率提供了九个目标C - 10碳环类似物(系列2(21 - 29))。抗疟评估表明,这些化合物在体外对氯喹耐药寄生虫的效力比青蒿素高4倍,活性约为蒿甲醚的两倍。基于从C - 10碳环类似物(23)的仿生Fe(II)降解获得的产物,我们提出这些类似物的作用模式可能与母体药物青蒿素(系列1(7 - 16))以及其他C - 10醚衍生物如蒿甲醚略有不同。世界卫生组织的初步体内测试表明,这些化合物中的四种在剂量低于10 mg/kg时口服具有活性。由于这些类似物可以作为水溶性盐获得,并且不能通过P450催化氧化形成二氢青蒿素,它们代表了可能被证明优于目前使用的衍生物蒿甲醚和青蒿琥酯的有用先导化合物。